Regeneron extends US agreement for additional supply of Ebola treatment
Regeneron extends US agreement for additional supply of Ebola treatment Reuters
Covered in this story
Analyst targets on Regeneron Pharmaceuticals
- Jefferies: $735 → $930 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $REGN yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Regeneron Pharmaceuticals →Summary aggregated from Reuters's public RSS feed. The full reporting belongs to Reuters — please read it on their site.